With the wind of the pandemic at its back, the biopharma industry saw a surging tide of fundraising in 2020 that has only exponentially grown this year, Enpoint News writes. But with VC dollars flowing like never before, are there some cracks showing in biopharma’s gold-tinted façade? In the first half of 2021, total healthcare venture spending in the US has already outstripped 2020’s record-breaking totals across biotech, healthtech and beyond, putting the industry on a funding pace that could be hard to match in coming years, according to a new report from Silicon Valley Bank released Wednesday. Read more.
Related Posts
2023 Median Ratios: Not-for-Profit Hospitals and Healthcare Systems Still Face Liquidity Challenges
Fitch Ratings’ 2023 medians (using audited 2022 data) largely show sizable and widespread deterioration in operating margins and balance sheet metrics.
July 26, 2023
Why the FTC is Watching CVS, Amazon’s Healthcare Deals
These deals are undergoing deep scrutiny from the FTC as investors have been increasingly cracking down on Big Tech mergers.
February 21, 2023
As HCA-Mission Lawsuit Awaits NC Judge’s Call, Officials Say Company was No-Show During Deal
The original complaint, filed Aug. 10, charges the Nashville-based hospital company with "restraint of trade and unlawful monopolization."
May 10, 2022
Latest Global Survey from ISAPS Reports a Rise in Aesthetic Surgery Worldwide
The report shows a 11.2% overall increase in procedures performed by plastic surgeons in 2022.
September 5, 2023